36results about How to "The composition of the prescription is simple" patented technology

The invention discloses an amoxicillin pharmaceutical preparation and a preparation method thereof. The amoxicillin pharmaceutical preparation comprises the following components in parts by mass: 90.0-99.9 parts of amoxicillin and 0.1-10.0 parts of magnesium stearate. The preparation method is a dry-press process. By controlling the particle size distribution of amoxicillin, the particle size distribution of magnesium stearate and the pressure of the dry press, excellent dissolution quantity and stability of the amoxicillin preparation can be ensured.

The invention belongs to the field of pharmaceutical preparations, and in particular relates to an orally disintegrating obeticholic acid tablet and a preparation method thereof. The orally disintegrating tablet of obeticholic acid of the present invention is composed of active ingredient obeticholic acid, filler, disintegrant, flavoring agent and lubricant, and its weight percentage is: 5‑12.5: 65‑75: 10‑20 : 1-6: 3-7. The invention adopts a powder direct tableting method to prepare obeticholic acid orally disintegrating tablets, and the process is simple and suitable for large-scale industrial production. The disintegration time, content uniformity, stability and the like of the obeticholic acid orally disintegrating tablet prepared by the present invention all meet the pharmacopoeia standards.

The invention relates to a huperzine osmotic-pump controlled release tablet, which is composed of tablet core containing huperzine and semipermeable film coating with small holes. The huperzine osmotic-pump controlled release preparation is characterized in that the preparation comprises the following components by the weight percent: 0.2-0.6 percent of huperzine in the tablet core, 85-95 percent of osmotic pressure accelerating agent, 1-10 percent of suspending agent and o.1-5 percent of other components. A coating film contains cellulose acetate, PEG (polyethyleneglycol) 4000 and a plasticizing agent, and the proportion of the cellulose acetate, the PEG4000 and the plasticizing agent is 1: (0.3-0.4) : (0.1-0.2). The weight of the coating is increased by 11-13 percent.

The invention belongs to the field of medicinal preparations, and discloses an indissolvable drug oral sustained-release dry emulsion tablet and a preparation method thereof. The preparation method for the oral sustained-release dry emulsion tablet comprises the steps that after an oil phase, a surface active agent and cosurfactant are evenly mixed, an indissolvable drug is added till the drug is dissolved completely, and accordingly a medicine-carried self-emulsifying system is prepared; after the medicine-carried self-emulsifying system and an aqueous solution of a hydrophilic gel framework material are evenly mixed, spray drying is conducted, and sustained-release dry emulsion powder is obtained; after the sustained-release dry emulsion powder and a conventional tablet auxiliary material needed for preparation are mixed, wet granulation is carried out; at last, tabletting is performed. The sustained-release dry emulsion tablet can improve the dissolution and dissolving-out performance of the indissolvable drug, the bioavailability of the indissolvable drug is improved, a stable blood concentration is formed, and the compliance of patients is improved. The sustained-release dry emulsion tablet is not complex in composition of prescription, and the preparation technology is suitable for industrial production.

The present invention relates to a nifedipine A crystal bulk crystal habit and a controlled release tablet composition thereof, the controlled release tablet composition contains (HPMC) E30 and the nifedipine A crystal habit, the nifedipine A crystal form is cubic, the length, width and thickness ratio is 4-1: 2-1: 1, the particle size range Dv (90) is 120-240 [mu] m, and the mass ratio of HPMC E30 to nifedipine is 2:1 to 3:1. The invention provides the nifedipine bulk crystal habit and a pharmaceutical composition of nifedipine controlled release tablets released at an approximately constantrate.

The invention belongs to the technical field of medicines, and relates to an oral cavity instant membrane agent containing rizatriptan benzoate prepared by using an electrostatic spinning technology.The formula of the oral cavity instant membrane agent comprises, 1 part of the rizatriptan benzoate, 1-300 parts of a membrane forming material and 0-50 parts of other auxiliaries. An oral cavity instant membrane is obtained through the electrostatic spinning technology, the electrostatic spinning conditions are that the voltage is 5-20 kV, the proceeding speed is 0.1-10 ml/h, the receiving distance is 5-20 cm, the temperature is 5-60 DEG C, and the humidity is 10-70%. The oral cavity instant membrane agent is composed of nano polymer fibers formed by electrostatic spinning, and the diameter of the nano polymer fibers is 10-1000 nm. The rizatriptan benzoate is uniformly distributed without a fixed form state. The oral cavity instant membrane agent containing the rizatriptan benzoate has higher specific surface area and porosity and faster dissolution rate, the effect comes up faster, the biological utilization rate is higher, and the pain of a patient with migraine can be rapidly relieved.

The invention provides a berberine-oryzanol tablet and application thereof in treatment of diabetes. The berberine-oryzanol tablet is obtained through mixing of modified berberine-oryzanol granules and other adjuvants at a certain ratio and tabletting of the mixture, wherein the modified granules comprise drugs, surfactants and dispersants. Through the modified granules, the solubility of berberine and oryzanol can be improved well, and the dissolution and bioavailability of the drugs can be improved. According to the tablet, a good treatment effect on diabetes can be achieved through compatibility of the drugs, a reasonable prescription and preparation process.

The invention relates to the field of pharmaceutical preparations, and provides an application of beta-glucan as an adhesive in the preparation of tablets or granules. Beta-glucan has certain viscosity, can play a certain role in adhesion in the tablet forming process, and can also ensure the dissolution of medicines. The invention further provides a pharmaceutical composition containing beta-glucan. Beta-glucan and a surfactant namely sodium dodecyl sulfate are jointly dispersed in an organic solvent, drying is carried out after sufficient stirring, airflow crushing is further carried out toobtain beta-glucan-sodium dodecyl sulfate modified powder, the dispersity of beta-glucan and the content uniformity of a preparation are effectively improved, and the medicine bioavailability is improved.

The invention belongs to the field of pharmaceutical preparations, and particularly relates to effervescent tablets containing a stiripentol solid dispersion and a preparation method thereof. According to the effervescent tablets disclosed by the invention, in one aspect, an indissolvable drug is prepared into an amorphous solid dispersion, so that the defect that the permeability of gastrointestinal tracts is reduced by other solubilizing means is overcome while the water solubility and the dissolution rate are improved, and the effervescent tablets have relatively high encapsulation efficiency (16.67%-50%); in the other aspect, a common, easily available and safe enteric-coated material is selected as a solid dispersion carrier to ensure that the stiripentol is released in the small intestine in a positioned manner and cannot be dissociated in advance in a physiological solution to cause damage of gastric acid to medicine like other preparation means; and besides, compared with commercially available dosage forms (capsules and dry suspensions), the effervescent tablets overcome the problem that the content is easy to cake, and has the advantages of stable storage, convenience in taking, good taste, particular suitability for epilepsy children who cannot swallow solid preparations, and the like.

A Chinese medicine in the form of tablet for nourishing qi and Yin, promoting blood circulation and pulse, heart blood stagnation, cardialgia, palpitation, etc is prepared from 6 Chinese-medicinal materials including ginseng, astragalus root, red sage root, Chuan-xiong rhizome, etc, lubricant and diluent (microcrystalline cellulose) through extracting in water, removing solvent to obtain powder and other conventional steps.

The invention provides a cetylpyridinium chloride-containing buccal tablet and a preparation technology thereof. The buccal tablet is prepared from cetylpyridinium chloride, xanthan gum, mannitol andmagnesium stearate. The buccal tablet has the advantages of simple prescription composition, great reduction of side effects possibly caused by auxiliary materials, safe and nontoxic auxiliary materials, obvious prolongation of the lasting time of the medicine effect, simple product process, convenience in large-scale production, and safe and reliable product quality. The buccal tablet solves theproblems of medication convenience and compliance of patients.

The invention provides a faropenem sodium capsule. The faropenem sodium capsule is characterized by being prepared from the following components in parts by weight on the basis of faropenem: 100 parts of faropenem sodium, 300-400 parts of filler, 8.0-80 parts of lubricant, 100-200 parts of dispersing agent and 10-50 parts of dry adhesive. The faropenem sodium capsule is prepared through a dry granulation technology, and the prepared faropenem sodium capsule solves the defect that the existing capsule is poor in stability.

The embodiment of the invention relates to the field of preparations, in particular to an arctiin compound entrapped local skin external preparation based on a solid particle emulsification technology and a preparation method and application of the arctiin compound entrapped local skin external preparation. The arctiin compound entrapped external preparation provided by the embodiment of the invention comprises the following components in parts by weight: 1-15 parts of arctiin or arctigenin, 0.5-10 parts of a solid particle emulsifier, 10-40 parts of an oil phase, 5-30 parts of a solubilizer and 1-10 parts of a thickening agent, wherein the particle size of the solid particle emulsifier is nanometer or micrometer. According to the arctiin compound entrapped external preparation provided by the embodiment of the invention, the arctiin compound forms a stable and efficient system through the solid particle emulsifier, and can stably release medicine in the medication process. In addition, compared with a traditional emulsion, the external preparation also enhances the skin permeability and retention property of the arctiin compound, and shows better pharmacological activity and curative effect.